IL2 and pancreatic ductal adenocarcinoma: We studied in detail the quality and quantity of cellular immune response of a 65-year old female patient diagnosed with pancreatic ductal adenocarcinoma (PDAC) and stage IV peritoneal metastasis, who received a single dose of 60mg/kg cyclophosphamide, followed by 2x10e9 TIL at day 2, with sequent 5 doses of IL-2 (600,000 IL-2/kg).